Cogent Biosciences Files 8-K on Financials

Ticker: COGT · Form: 8-K · Filed: Aug 5, 2025 · CIK: 1622229

Cogent Biosciences, INC. 8-K Filing Summary
FieldDetail
CompanyCogent Biosciences, INC. (COGT)
Form Type8-K
Filed DateAug 5, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: financial-reporting, 8-K

TL;DR

Cogent Biosciences dropped an 8-K on financials, check it out.

AI Summary

Cogent Biosciences, Inc. filed an 8-K on August 5, 2025, reporting on its results of operations and financial condition. The filing also includes financial statements and exhibits. The company was formerly known as Unum Therapeutics Inc. and Unum Therapeutics, Inc.

Why It Matters

This filing provides an update on Cogent Biosciences' financial status and operational results, which is crucial for investors to assess the company's performance and future prospects.

Risk Assessment

Risk Level: low — This is a routine financial filing and does not indicate any immediate or significant risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report on Cogent Biosciences, Inc.'s results of operations and financial condition, and to include financial statements and exhibits.

When was this 8-K report filed?

This 8-K report was filed on August 5, 2025.

What was Cogent Biosciences, Inc. formerly known as?

Cogent Biosciences, Inc. was formerly known as Unum Therapeutics Inc. and Unum Therapeutics, Inc.

Where is Cogent Biosciences, Inc. headquartered?

Cogent Biosciences, Inc. is headquartered at 275 Wyman Street, 3rd Floor, Waltham, Massachusetts 02451.

What is the Standard Industrial Classification code for Cogent Biosciences, Inc.?

The Standard Industrial Classification code for Cogent Biosciences, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on August 5, 2025 regarding Cogent Biosciences, Inc. (COGT).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing